$DRTX climber. FDA after hours. $16.89

Fri, May 23, 2014, 5:21pm EDT
FDA Approves Durata Therapeutics' DALVANCE(TM)
for the Treatment of Acute Bacterial Skin
and Skin Structure Infections.
news release

Low Float
10-Q 5/8/14
O/S shares 26,641,975


Website


recent trades
Stockwatch


Consensus

Nasdaq
Durata Therapeutics: FDA Okays Dalvance To Treat Skin Infections
5/23/2014 4:32:00 PM - RTT News
FDA Approves Durata Therapeutics' DALVANCE(TM) for the
Treatment of Acute Bacterial Skin and Skin Structure Infections
(ABSSSI) Caused by Susceptible Gram-Positive Bacteria,
Including MRSA, in Adults
5/23/2014 4:17:00 PM - GlobeNewswire
Sector Update: Healthcare Shares Mixed Pre-Market; Durata up
2.4% on Buy Rating at MLV
5/23/2014 8:33:43 AM - MT Newswires
Sector Update: Healthcare
5/23/2014 8:32:04 AM - MT Newswires
Watch List for Equities Hitting New High -- Research on SanDisk,
Universal Health Services, Sesa Sterlite and Durata Therapeutics
5/21/2014 10:44:00 AM - PR Newswire


% Buy Opinion (composite)